Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
13.55
+7.99 (143.71%)
At close: Nov 20, 2024, 4:00 PM
12.21
-1.34 (-9.89%)
Pre-market: Nov 21, 2024, 4:27 AM EST
Forte Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 77.58, with a low estimate of 64 and a high estimate of 100. The average target predicts an increase of 472.55% from the current stock price of 13.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FBRX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3 → $64 | Strong Buy | Maintains | $3 → $64 | +372.32% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +453.51% | Aug 19, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +638.01% | May 30, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $69 | Hold → Strong Buy | Upgrades | $69 | +407.38% | Apr 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades $100 → $88 | Strong Sell → Hold | Upgrades | $100 → $88 | +545.76% | Sep 20, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-22.95
from -24.92
EPS Next Year
-18.62
from -22.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -22.84 | -16.01 | -20.74 | ||
| Avg | -22.95 | -18.62 | -20.15 | ||
| Low | -22.79 | -20.83 | -19.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.